Astellas Pharma Inc. (JOBS) Scraps Agreement with Neurosearch A/S on ACR16

Published: Mar 04, 2009

TOKYO, March 3 (Reuters) - Astellas Pharma Inc, Japan's second-biggest drugmaker, said on Tuesday that it has scrapped its licensing agreement with a Neurosearch A/S unit on a drug to treat schizophrenia.

Back to news